Cuu Long Pharmaceutical JSC

Cuu Long Pharmaceutical JSC FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cuu Long Pharmaceutical JSC (DCL.VN) as of Oct 29, 2026 is -192.34 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -1,345.49 % — a change of -85.71% (higher).

FCF Conversion

-192.34 %

YoY

-85.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cuu Long Pharmaceutical JSC is 2024 -192.34 % . FCF Conversion Rate (FCF/EBITDA) of Cuu Long Pharmaceutical JSC was 2023 -1,345.49 % . It decreases by -85.71% higher compared to the previous year.

The Cuu Long Pharmaceutical JSC FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
126.12 VND
Jan 1, 2015
98.29 VND
Jan 1, 2016
37.36 VND
Jan 1, 2017
-139.56 VND
Jan 1, 2018
-1,345.49 VND
Jan 1, 2024
-192.34 VND
The Cuu Long Pharmaceutical JSC FCF Conversion history
YEARFCF ConversionYoY
-192.34 %-85.71%
-1,345.49 %+864.10%
-139.56 %-473.59%
37.36 %-62.00%
98.29 %-22.06%
126.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuu Long Pharmaceutical JSC Stock analysis

What does Cuu Long Pharmaceutical JSC do? Cuu Long Pharmaceutical JSC manufactures and sells pharmaceuticals, capsules, and medical instruments, including functional food, cosmetics, and chemicals for pharmaceutical production. The company imports and exports these products, and also produces specialized packaging for drugs and medical products. It cultivates traditional herbs as part of its operations. The firm targets domestic and international markets for its pharmaceutical and medical product lines, with a focus on manufacturing and distribution. Its products are sold to healthcare providers, pharmacies, and consumers through its own channels and partnerships. Cuu Long Pharmaceutical JSC's revenue streams include the sale of manufactured pharmaceuticals, capsules, medical instruments, functional food, cosmetics, and chemicals. The company also generates income from the export and import of these goods. Specialized packaging for drug and medical product manufacturers is another key revenue source. The cultivation of traditional herbs supports its production of herbal-based pharmaceuticals and supplements. The company serves healthcare providers, pharmacies, and consumers in domestic and international markets. Its product portfolio includes pharmaceutical drugs, capsules, medical equipment, functional food, cosmetics, and herbal products. The firm's manufacturing and distribution capabilities allow it to supply both B2B and B2C segments within the healthcare and wellness industry. Cuu Long Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cuu Long Pharmaceutical JSC stock

FCF Conversion Rate (FCF/EBITDA) of Cuu Long Pharmaceutical JSC is -192.34 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Cuu Long Pharmaceutical JSC changed from -1,345.49 % to -192.34 %, representing a -85.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cuu Long Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cuu Long Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cuu Long Pharmaceutical JSC

All Key Metrics — Cuu Long Pharmaceutical JSC